Webinar

Breaking barriers and moving forward: Reflections on impact and future directions for CGT

Industrialization and advancements in manufacturing were identified as crucial factors in scaling up CGTs effectively, with the importance of embracing new technologies to streamlined processes and deliver life-changing medicines on a larger scale. The conversation also underscored collaboration among stakeholders as key to advancing patient empowerment and access globally.  
 
Fill out the form below to watch the full recording for deeper insights into the transformative world of CGT. 

 

Pardot Form
headshot

A glimpse into the future of CGTs with ARM’s Rita Johnson-Greene

Breakthroughs with cell and gene therapy innovation are transforming the therapeutic landscape, with a number of approvals in the US and EU and more in the pipeline. This issue has been top of mind during many sessions throughout Cencora’s two-day ThinkLive CGT Summit. In this impactful meeting, Cencora’s Lung-I Cheng, Ph.D., Vice President and Head of Cell and Gene Therapy, joined Rita Johnson-Greene, Chief Operating Officer, Alliance for Regenerative Medicine (ARM) to reflect on the current and future state of CGT innovation.

Related resources

Webinar

Data Governance & AI in Pharma: Overcoming challenges in DACH region
Learn More

White paper

Capitalizing on biotech collaboration: A CFO’s guide to driving growth
Learn More

Article

The future promise of advanced therapies in ophthalmology
Learn More

We’re here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.
headshot
The ThinkLive Cell and Gene Therapy Summit 2024 culminated in a dynamic fireside chat focusing on the future of cell and gene therapy (CGT). 
headshot
We were pleased to welcome Rita Johnson-Greene, Chief Operating Officer, Alliance for Regenerative Medicine (ARM), to delve into overcoming obstacles in the CGT domain, and exploring strategies to empower patients and enhance access. 

Sharing perspectives on the evolving CGT landscape over the next few years, Mrs. Johnson-Greene explored the significant strides made in gene therapy approvals in 2024, underlining the maturation of regenerative medicine through increased competition among therapies targeting various diseases. She emphasized competition and globalization as key drivers for innovation, leading to lower costs and expanded patient access.
headshot

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.